NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

Tender description

NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>The period of the framework is 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Lot 1: Lot 1 - Low and High Strength Albumin NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents. Lot 2: Lot 2 - 5% Intravenous Immunoglobulin NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents. Lot 3: Lot 3 - 10% Intravenous Immunoglobulin NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents. Lot 4: Lot 4 - Subcutaneous Immunoglobulin NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents. Lot 5: Lot 5 - Facilitated Subcutaneous Immunoglobulin NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents. Lot 6: Lot 6 - Anti-D Immunoglobulin NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin<br/><br/>Offer reference number: CM/PHS/23/5703<br/><br/>Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.